Diabetes Drugs Market

Diabetes Drugs Market (Therapy - Glucagon-like Peptide-1 (GLP-1) Agonist, Dipeptidyl-peptidase-4 (DPP-4) Inhibitors, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors, and Insulin; Disease Type - Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Impaired Glucose Tolerance and Impaired Fasting Glycaemia; By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Diabetes Drug Market: Overview

Sedentary lifestyle, overweight, and age are some of the major factors contributing to growing prevalence of diabetes cases across the globe. As per a report published by the World Health Organization (WHO), in 2014, approximately 1.9 billion people were identified as overweight wherein 600 million were categorized as obese.

Obesity and overweight are major risk factors resulting in diabetes. Increasing incidence of diabetes is explicitly fuelling demand for diabetes drugs.

Registering the demand rate, the global diabetes drugs market is anticipate to witness robust growth rate in forthcoming years.

Growing geriatric population across the world is one of the major factor fuelling demand for diabetes drugs. Elderly population is highly susceptible to certain health conditions such as blood pressure and diabetes. This, in turn, is contributing to growth of the diabetes drugs market.

Diabetes is chronic condition, where body stops production of insulin, or inhibit its absorption. As a result, blood glucose level fluctuates significantly. To regulate blood glucose level, diabetic people are supposed to be on regular diabetes medication.

As per a report published by Transparency Market Research (TMR), the diabetes drugs market is estimated to chart at a moderate CAGR of 3.6% between 2017 and 2025. At given rate, the market valuation is calculated to reach at US$58.4 bn by the end of 2025, whereas the market stood at a value of US$43.1 bn in 2016.

global-diabetes-drugs-market.jpg

Distribution Channel Enhance Visibility of Diabetes Drugs

The global diabetes drugs market is segmented on the basis of glucagon-like peptide-1 agonist, sodium glucose co-transporter 2 inhibitors, insulin, Dipeptidyl-peptidase-4 (DPP-4) inhibitors, and others. Among all, insulin holds the prominent position in the market.

Distribution channel plays a crucial role in expansion of the market and enhancing visibility of the product. Hence, diabetes drugs market is classified into retail pharmacies, hospital pharmacies, and online pharmacies. Hospital pharmacies is likely to hold prominent share in the market due to presence of trained medical staffs to sell the medicines.  Due to rising popularity of e-tail and proliferation of e-commerce, online pharmacies seems to be a promising segment for growth of the diabetes drugs market.

Type 2 Diabetes Holds Prominent Position

Diabetes is categorized into type 1 diabetes, type 2 diabetes, impaired fasting glycaemia, impaired glucose tolerance, and gestational diabetes. Among all types of diabetes, type 2 segment contribute significantly to the diabetes drugs market, due its higher prevalence across the globe. Rising cases of obesity, rising disposable income, and improving healthcare facilities are some of the key factors propelling growth of diabetes type 2 segment. Type 1 diabetes is anticipated to follow type 2 segment. Meanwhile, impaired glucose tolerance, gestational diabetes, and impaired fasting segments are estimated to rise at a moderate pace during the forecast period.

Region wise, North America market holds prominent share in the year 2016 and is likely to hold its position due to high prevalence of diabetes in the region.

Meanwhile, Europe market holds second largest share in the year 2016 due to research and development activities for drug improvisation.

Some of the top companies operating in the global diabetes drugs market are Novo Nordisk A/S, Boehringer Ingelheim GmbH, Novartis AG, Bayer AG, Merck & Co., and Sanofi. Some other prominent companies operating in this market are Takeda Pharmaceutical Company Limited, Johnson & Johnson, Boehringer Ingelheim GmbH, and Eli Lily and Company.

Type-2 Diabetes Key Focus of Players in Diabetes Drugs Market

There is a growing body of research behind antidiabetic medications as to who actually need and what type is the most effective and safe for the patient cohort. A key driver for the diabetes drugs market is the high risks the disease brings to the patient, particularly in patients with type-2 diabetes. Extensive research has been made by drugmakers to develop formulations that can help lower the cardiovascular risks in patient populations, thereby expanding the growth potential in the diabetes drugs market. Some of the popular antidiabetic drugs are metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, glitazones, SGLT2 inhibitors, and glinides. However, not every patient with type-2 diabetes may need medication. The decision to continue with certain medications should be based on sound clinical decision, wherein physicians’ recommendations occupy critical position. Over the past few years, incretin mimetics has also gained some attention among industry players operating in the diabetes drugs market. However, the verdict is still out of its long-term advantages. The worldwide prevalence of diabetes will continue to propel drugmakers to enrich their drug pipeline to meet the unmet need in patient populations. They are relentlessly aiming at reducing the side effects and increase the safety profiles. The recent approval of pharmacological agents is a key developmental trend that will spur growth in the market.

The current Covid-19 pandemic has reiterated the criticality of managing chronic diseases and their role in public health. Diabetics are one of the cohorts that have at the forefront of high risk factors for being infected badly with the virus. Thus, the population healthcare systems are emphasizing on consolidating the infrastructure to improve care for chronic diseases, including diabetes and cardiovascular diseases. This also has changed the current course of development for drug makers to an extent, encouraging research and development investments in the diabetes drugs market. Also, the growing awareness among the general populace will help in patients make more clinically-informed decisions on the pharmacological therapies they need.

Diabetes Drugs Market has been segmented as given below:

by Therapy

  • Glucagon-like peptide-1 (GLP-1) agonist
  • Dipeptidyl-peptidase-4 (DPP-4) inhibitors
  • Sodium glucose co-transporter 2 (SGLT2) inhibitors
  • Insulin
  • Others

by Disease Type

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Impaired Glucose Tolerance and Impaired Fasting Glycaemia

by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America

    1. Preface
         1.1. Market Segmentation
         1.2. Key Research Objectives
         1.3. Research Highlights

    2. Assumptions and Research Methodology
         2.1. Secondary Research Methodology
         2.2. Primary Research Methodology
         2.3. Analysis Research Methodology
         2.4. Final Report & Conclusions Research Methodology

    3. Executive Summary: Global Diabetes Drugs Market

    4. Market Overview
         4.1. Introduction
                4.1.1. Therapy Definition
                4.1.2. Industry Evolution / Developments
         4.2. Overview
         4.3. Key Market Indicators
                4.3.1. Region/Country Specific
                4.3.2. Product/Application/Technology Specific
                4.3.3. Target Market Specific – Global Scenario
         4.4. Market Dynamics
                4.4.1. Drivers
                4.4.2. Restraints
                4.4.3. Opportunity
                4.4.3. Opportunity Analysis
                4.4.4. Trends
         4.5. Global Diabetes Drugs Market Analysis and Forecasts, 2015–2025
         4.6. Porter’s Five Forces Analysis 
         4.7. Value Chain Analysis 
         4.8. Pipeline Analysis 

    5. Global Diabetes Drugs Market Analysis and Forecasts, By Therapy 
         5.1. Introduction & Definition
         5.2. Key Findings / Developments
         5.3. Key Trends
         5.4. Market Value Forecast by Therapy, 2015–2025
                5.4.1. Glucagon-like peptide-1 (GLP-1) agonist
                5.4.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
                5.4.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
                5.4.4. Insulin
                5.4.5. Others
         5.5. Market Attractiveness by Therapy 

    6. Global Diabetes Drugs Market Analysis and Forecasts, By Disease Type 
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Key Trends
         6.4. Market Value Forecast by Disease Type, 2015–2025
                6.4.1. Type 1 Diabetes
                6.4.2. Type 2 Diabetes
                6.4.3. Gestational Diabetes
                6.4.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
         6.5. Disease Type Comparison Matrix
         6.6. Market Attractiveness by Disease Type 

    7. Global Diabetes Drugs Market Analysis and Forecasts, By Distribution Channel 
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Key Trends
         7.4. Market Value Forecast by Distribution Channel, 2015–2025
                7.4.1. Hospital Pharmacies
                7.4.2. Retail Pharmacies
                7.4.3. Online Pharmacies
         7.5. Distribution Channel Comparison Matrix
         7.6. Market Attractiveness by Distribution Channel 

    8. Global Diabetes Drugs Market Analysis and Forecasts, By Region
         8.1. Key Findings
         8.2. Policies and Regulations
         8.3. Market Value Forecast by Region
                8.3.1. North America 
                8.3.2. Europe 
                8.3.3. Asia Pacific 
                8.3.4. Middle East & Africa 
                8.3.5. Latin America 
         8.4. Market Attractiveness by Country/Region

    9. North America Diabetes Drugs Market Analysis and Forecast
         9.1. Introduction
                9.1.1. Key Findings
                9.1.2. Policies and Regulations
                9.1.3. Price Trend Analysis
                9.1.4. Key Trends
         9.2. Market Value Forecast by Therapy, 2015–2025
                9.2.1. Glucagon-like peptide-1 (GLP-1) agonist
                9.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
                9.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
                9.2.4. Insulin
                9.2.5. Others
         9.3. Market Value Forecast by Disease Type, 2015–2025
                9.3.1. Type 1 Diabetes
                9.3.2. Type 2 Diabetes
                9.3.3. Gestational Diabetes
                9.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
         9.4. Market Value Forecast by Distribution Channel, 2015–2025
                9.4.1. Hospital Pharmacies
                9.4.2. Retail Pharmacies
                9.4.3. Online Pharmacies
         9.5. Market Value Forecast by Country, 2015–2025
                9.5.1. U. S. 
                9.5.2. Canada
         9.6. Market Attractiveness Analysis 
                9.6.1. by Therapy 
                9.6.2. by Disease Type 
                9.6.3. by Distribution Channel 
                9.6.4. by Country
         9.7. Key Trends

    10. Europe Diabetes Drugs Market Analysis and Forecast
         10.1. Introduction
                10.1.1. Key Findings
                10.1.2. Policies and Regulations
                10.1.3. Price Trend Analysis
                10.1.4. Key Trends
         10.2. Market Value Forecast by Therapy, 2015–2025
                10.2.1. Glucagon-like peptide-1 (GLP-1) agonist
                10.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
                10.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
                10.2.4. Insulin
                10.2.5. Others
         10.3. Market Value Forecast by Disease Type, 2015–2025
                10.3.1. Type 1 Diabetes
                10.3.2. Type 2 Diabetes
                10.3.3. Gestational Diabetes
                10.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
         10.4. Market Value Forecast by Distribution Channel, 2015–2025
                10.4.1. Hospital Pharmacies
                10.4.2. Retail Pharmacies
                10.4.3. Online Pharmacies
         10.5. Market Value Forecast by Country, 2015–2025
                10.5.1. Germany 
                10.5.2. France
                10.5.3. Italy 
                10.5.4. Spain 
                10.5.5. UK
                10.5.6. Rest of Europe
         10.6. Market Attractiveness Analysis 
                10.6.1. by Therapy 
                10.6.2. by Disease Type 
                10.6.3. by Distribution Channel 
                10.6.4. by Country
         10.7. Key Trends

    11. Asia Pacific Diabetes Drugs Market Analysis and Forecast
         11.1. Introduction
                11.1.1. Key Findings
                11.1.2. Policies and Regulations
                11.1.3. Price Trend Analysis
                11.1.4. Key Trends
         11.2. Market Value Forecast by Therapy, 2015–2025
                11.2.1. Glucagon-like peptide-1 (GLP-1) agonist
                11.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
                11.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
                11.2.4. Insulin
                11.2.5. Others
         11.3. Market Value Forecast by Disease Type, 2015–2025
                11.3.1. Type 1 Diabetes
                11.3.2. Type 2 Diabetes
                11.3.3. Gestational Diabetes
                11.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
         11.4. Market Value Forecast by Distribution Channel, 2015–2025
                11.4.1. Hospital Pharmacies
                11.4.2. Retail Pharmacies
                11.4.3. Online Pharmacies
         11.5. Market Value Forecast by Country, 2015–2025
                11.5.1. China
                11.5.2. Japan
                11.5.3. India
                11.5.4. Australia & New Zealand
                11.5.5. Rest of Asia Pacific
         11.6. Market Attractiveness Analysis 
                11.6.1. by Therapy 
                11.6.2. by Disease Type 
                11.6.3. by Distribution Channel 
                11.6.4. by Country
         11.7 Key Trends

    12. Middle East & Africa Diabetes Drugs Market Analysis and Forecast
         12.1. Introduction
                12.1.1. Key Findings
                12.1.2. Policies and Regulations
                12.1.3. Price Trend Analysis
                12.1.4. Key Trends
         12.2. Market Value Forecast by Therapy, 2015–2025
                12.2.1. Glucagon-like peptide-1 (GLP-1) agonist
                12.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
                12.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
                12.2.4. Insulin
                12.2.5. Others
         12.3. Market Value Forecast by Disease Type, 2015–2025
                12.3.1. Type 1 Diabetes
                12.3.2. Type 2 Diabetes
                12.3.3. Gestational Diabetes
                12.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
         12.4. Market Value Forecast by Distribution Channel, 2015–2025
                12.4.1. Hospital Pharmacies
                12.4.2. Retail Pharmacies
                12.4.3. Online Pharmacies
         12.5. Market Value Forecast by Country, 2015–2025
                12.5.1. GCC Countries
                12.5.2. South Africa
                12.5.3. Rest of Middle East & Africa
         12.6. Market Attractiveness Analysis 
                12.6.1. by Therapy 
                12.6.2. by Disease Type 
                12.6.3. by Distribution Channel 
                12.6.4. by Country
         12.7. Key Trends

    13. Latin America Diabetes Drugs Market Analysis and Forecast
         13.1. Introduction
                13.1.1. Key Findings
                13.1.2. Policies and Regulations
                13.1.3. Price Trend Analysis
                13.1.4. Key Trends
         13.2. Market Value Forecast by Therapy, 2015–2025
                13.2.1. Glucagon-like peptide-1 (GLP-1) agonist
                13.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
                13.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
                13.2.4. Insulin
                13.2.5. Others
         13.3. Market Value Forecast by Disease Type, 2015–2025
                13.3.1. Type 1 Diabetes
                13.3.2. Type 2 Diabetes
                13.3.3. Gestational Diabetes
                13.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
         13.4. Market Value Forecast by Distribution Channel, 2015–2025
                13.4.1. Hospital Pharmacies
                13.4.2. Retail Pharmacies
                13.4.3. Online Pharmacies
         13.5. Market Value Forecast by Country, 2015–2025
                13.5.1. Brazil
                13.5.2. Mexico
                13.5.3. Rest of Latin America
         13.6. Market Attractiveness Analysis 
                13.6.1. by Therapy 
                13.6.2. by Disease Type 
                13.6.3. by Distribution Channel 
                13.6.4. by Country
         13.7. Key Trends

    14. Competition Landscape
         14.1. Competition Matrix
         14.2. Market Share Analysis by Company (2015)
         14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
                14.3.1. Novo Nordisk A/S
                          14.3.1.1. Company Description
                          14.3.1.2. Financial Overview
                          14.3.1.3. Strategic Overview
                          14.3.1.4. Recent Developments
                          14.3.1.5. SWOT ANALYSIS
                14.3.2. Sanofi
                          14.3.2.1. Company Description
                          14.3.2.2. Financial Overview
                          14.3.2.3. Strategic Overview
                          14.3.2.4. Recent Developments
                          14.3.2.5. SWOT ANALYSIS
                14.3.3. Merck & Co., Inc. 
                          14.3.3.1. Company Description
                          14.3.3.2. Financial Overview
                          14.3.3.3. Strategic Overview
                          14.3.3.4. Recent Developments
                          14.3.3.5. SWOT ANALYSIS
                14.3.4. Eli Lilly and company
                          14.3.4.1. Company Description
                          14.3.4.2. Financial Overview
                          14.3.4.3. Strategic Overview
                          14.3.4.4. Recent Developments
                          14.3.4.5. SWOT ANALYSIS
                14.3.5. AstraZeneca
                          14.3.5.1. Company Description
                          14.3.5.2. Financial Overview
                          14.3.5.3. Strategic Overview
                          14.3.5.4. Recent Developments
                          14.3.5.5. SWOT ANALYSIS
                14.3.6. Boehringer Ingelheim GmbH
                          14.3.6.1. Company Description
                          14.3.6.2. Financial Overview
                          14.3.6.3. Strategic Overview
                          14.3.6.4. Recent Developments
                          14.3.6.5. SWOT ANALYSIS
                14.3.7. Johnson & Johnson
                          14.3.7.1. Company Description
                          14.3.7.2. Financial Overview
                          14.3.7.3. Strategic Overview
                          14.3.7.4. Recent Developments
                          14.3.7.5. SWOT ANALYSIS
                14.3.8. Novartis AG
                          14.3.8.1. Company Description
                          14.3.8.2. Financial Overview
                          14.3.8.3. Strategic Overview
                          14.3.8.4. Recent Developments
                          14.3.8.5. SWOT ANALYSIS
                14.3.9. Takeda Pharmaceutical Company Limited
                          14.3.9.1. Company Description
                          14.3.9.2. Financial Overview
                          14.3.9.3. Strategic Overview
                          14.3.9.4. Recent Developments
                          14.3.9.5. SWOT ANALYSIS
                14.3.10. Bayer AG
                          14.3.10.1. Company Description
                          14.3.10.2. Financial Overview
                          14.3.10.3. Recent Developments
                          14.3.10.4. SWOT ANALYSIS

    List of Tables

    Table 1: Opportunity Map, 2016
    Table 2: Opportunity Map, 2016
    Table 3: Opportunity Map, 2016
    Table 4: Pipeline Analysis, By Phase 3 Drugs
    Table 5: Pipeline Analysis, By Phase 2 (1/2)
    Table 6: Pipeline Analysis, by phase 2 (2/2)
    Table 7: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Therapy, 2015–2025
    Table 8: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 9: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 10: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 11: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
    Table 12: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 13: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 14: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 15: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
    Table 16: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 17: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 18: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 19: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
    Table 20: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 21: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 22: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 23: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy,
    Table 24: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 25: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 26: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
    Table 27: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
    Table 28: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
    Table 29: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 30: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025

    List of Figures

    Figure 01: Diabetes Drugs Market, by Therapy, Market Size (US$ Mn), 2016 (A)
    Figure 02: Diabetes Drugs Market Revenue (%), by Disease Type, 2016 (A)
    Figure 03: Global Diabetes Drugs Market Size (US$ Mn) Forecast, 2015–2025
    Figure 04: Global Diabetes Drugs Market Value Share, by Therapy (2016)
    Figure 05: Global Diabetes Drugs Market Value Share, by Disease Type (2016)
    Figure 06: Global Diabetes Drugs Market Value Share, by Distribution Channel (2016)
    Figure 07: Global Diabetes Drugs Market Value Share, by Therapy, 2016 and 2025
    Figure 08: Global Diabetes Drugs Market Attractiveness, by Therapy, 2017–2025
    Figure 09: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by GLP-1, 2015–2025
    Figure 10: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DPP-4, 2015–2025
    Figure 11: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by SGLT-2, 2015–2025
    Figure 12: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Insulin, 2015–2025
    Figure 13: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
    Figure 14: Global Diabetes Drugs Market Value Share, by Disease Type, 2016 and 2025
    Figure 15: Global Diabetes Drugs Market Attractiveness, by Disease Type, 2017–2025
    Figure 16: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Type 1 Diabetes, 2015–2025
    Figure 17: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Type 2 Diabetes, 2015–2025
    Figure 18: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Gestational Diabetes, 2015–2025
    Figure 19: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Impaired Glucose Tolerance and Impaired Fasting Glycaemia, 2015–2025
    Figure 20: Global Diabetes Drugs Market Value Share, by Distribution Channel, 2016 and 2025
    Figure 21: Global Diabetes Drugs Market Attractiveness, by Distribution Channel, 2017–2025
    Figure 22: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
    Figure 23: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
    Figure 24: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
    Figure 25: Global Diabetes Drugs Market Value Share, by Region, 2017 and 2025 
    Figure 26: Global Diabetes Drugs Market Attractiveness, by Region, 2017–2025
    Figure 27: North America Diabetes Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
    Figure 28: North America Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
    Figure 29: North America Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 30: North America Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 31: North America Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 32: North America Diabetes Drugs Market Attractiveness Analysis, by Therapy
    Figure 33: North America Diabetes Drugs Market Attractiveness Analysis, by Disease Type
    Figure 34: North America Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
    Figure 35: North America Diabetes Drugs Market Attractiveness Analysis, by Country
    Figure 36: Europe Diabetes Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
    Figure 37: Europe Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
    Figure 38: Europe Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 39: Europe Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 40: Europe Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 41: Europe Diabetes Drugs Market Attractiveness Analysis, by Therapy
    Figure 42: Europe Diabetes Drugs Market Attractiveness Analysis, by Disease Type
    Figure 43: Europe Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
    Figure 44: Europe Diabetes Drugs Market Attractiveness Analysis, by Country/Sub-region
    Figure 45: Asia Pacific Diabetes Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 46: Asia Pacific Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
    Figure 47: Asia Pacific Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 48: Asia Pacific Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 49: Asia Pacific Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 50: Asia Pacific Diabetes Drugs Market Attractiveness Analysis, by Therapy
    Figure 51: Asia Pacific Diabetes Drugs Market Attractiveness Analysis, by Disease Type
    Figure 52: Asia Pacific Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
    Figure 53: Asia Pacific Diabetes Drugs Market Attractiveness Analysis, by Country
    Figure 54: Middle East & Africa Diabetes Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 55: Middle East & Africa Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
    Figure 56: Middle East & Africa Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 57: Middle East & Africa Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 58: Middle East & Africa Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 59: Middle East & Africa Diabetes Drugs Market Attractiveness Analysis, by Therapy
    Figure 60: Middle East & Africa Diabetes Drugs Market Attractiveness Analysis, by Disease Type
    Figure 61: Middle East & Africa Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
    Figure 62: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region
    Figure 63: Latin America Diabetes Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 64: Latin America Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
    Figure 65: Latin America Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
    Figure 66: Latin America Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 67: Latin America Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 68: Latin America Diabetes Drugs Market Attractiveness Analysis, by Therapy
    Figure 69: Latin America Diabetes Drugs Market Attractiveness Analysis, by Disease Type
    Figure 70: Latin America Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
    Figure 71: Latin America Market Attractiveness Analysis, by Country/Sub-region
    Figure 72: Global Diabetes Drugs Market Share, by Company, 2016

Copyright © Transparency Market Research, Inc. All Rights reserved